Please assess the completion status of the following clinical trial:

Trial Title: A Study of Olaratumab in Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The participant has histologically- or cytologically-confirmed malignant soft tissue sarcoma~* The participant has advanced soft tissue sarcoma (STS), not amenable to treatment with surgery or radiotherapy~* The participant's Eastern Cooperative Oncology Group (ECOG) performance status is 0-2~* The participant has available tumor tissue from either the primary or metastatic tumor for determination of PDGFRα expression~* The participant has adequate hematologic function as defined by an absolute neutrophil count (ANC) ≥ 1500 μL, hemoglobin ≥ 9.0 g/dL, and a platelet count of 100,000/μL obtained within 2 weeks prior to study entry~* The participant has adequate hepatic function as defined by a total bilirubin ≤ 1.5 mg/dL, and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 times the upper limit of normal (ULN)~* The participant has adequate renal function as defined by serum creatinine ≤ 1.5 × the institutional ULN. If creatinine is above the ULN, the participant's creatinine clearance is ≥ 45 mL/min~* Because the teratogenicity of Olaratumab is not known, women of childbearing potential (WOCBP) and sexually active males must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation~Exclusion Criteria:~* The participant has histologically- or cytologically-confirmed Kaposi's sarcoma~* The participant has untreated central nervous system metastases~* The participant received prior treatment with doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones (ie, mitoxantrone)~* The participant received prior radiation therapy to the mediastinal/pericardial area~* The participant has a history of another primary cancer, with the exception of a) curatively resected nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor treated with curative intent, no known active disease present, and no treatment administered during the last 3 years prior to study entry~* The participant is receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemo-embolization, targeted therapy, or an investigational agent~* The participant has an elective or a planned major surgery to be performed during the course of the study~* The participant has an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, requiring parenteral antibiotics, symptomatic congestive heart failure, severe myocardial insufficiency, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* The participant has unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 6 months prior to study entry~* The participant has known immunodeficiency virus (HIV) infection~* The participant, if female, is pregnant or lactating~* The participant has a known allergy to any of the treatment components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1b: Olaratumab + doxorubicin (Type: EXPERIMENTAL): All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8
- Phase 2: Olaratumab and doxorubicin (Type: EXPERIMENTAL): All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8
- Phase 2: Doxorubicin: Optional Olaratumab After Progression (Type: ACTIVE_COMPARATOR): All cycles are 21 days.~Cycles 1-8: doxorubicin 75 mg/m2 on day 1 until disease progression.~At disease progression: optional Olaratumab 15 mg/kg on days 1+8 until further progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).